INSIGHTS AND PERSPECTIVES

HAYWARD, Calif. — An investigational drug for Parkinson’s disease was safe and effective, according to results of a late-stage clinical trial scheduled for presentation next week.

Impax Pharmaceuticals, the branded products division of Impax Labs, said it would present data from a phase-3 trial of extended-release IPX066 (carbidopa-levodopa) at the American Academy of Neurology Conference’s annual meeting in Hawaii, which takes place from April 9 through April 16.

The company also said there were no unexpected serious side effects observed in patients.

WHAT IT MEANS AND WHY IT'S IMPORTANT — The news that CVS Caremark has named Helena Foulkes EVP and chief healthcare strategy and marketing officer undoubtedly is significant, as she will be responsible for integrating all the company's capabilities in branding, communications and healthcare-reform strategy to forge even stronger partnerships and further improve pharmacy care delivery.

NEW YORK — Patients diagnosed with high blood-glucose levels that cannot control the condition over time likely will develop such eye-related complications as retinopathy 10 years later, according to a report in the February issue of Archives of Ophthalmology.

WASHINGTON — The American Enterprise Institute for Public Policy Research on Monday published a working paper that identified $329 million in overspending as a result of underutilization of generics.

As total spending on 20 medicines with generic equivalents totaled approximately $1.5 billion, AEI concluded Medicaid overspent by 22% ($1.5 billion versus $1.17 billion) on these pharmaceuticals.

NEW YORK — Patients that have been handling their diabetes for a long time are less likely to experience complications, according to a new study conducted by Joslin Diabetes Center researchers.

Among 351 participants in the "Joslin 50-Year Medalist Study," researchers found that among veteran Type 1 diabetics — who have been living with the condition for 50 years or more — 43% were free from advanced diabetic eye complications, while 87% were free from kidney disease, 39% were free from nerve disease and 52% were free from cardiovascular disease.

MIAMI BEACH — While fewer consumers are seeking out private-label options this year, preplanning activities continue to be a priority, according to a new survey conducted by SymphonyIRI Group.

In SymphonyIRI's inaugural MarketPulse survey, the group found that 2-out-of-3 shoppers today are making shopping lists prior to visiting the store, while 56% are reading store fliers either before or at the store — statistics that are in line with trends noted in 2010.

CLEVELAND — A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

Researchers at Case Western Reserve University took specially bred obese, prediabetic rats and gave them either Merck’s Januvia (sitagliptin), placebo or glyburide, an older diabetes drug. Both of the diabetes drugs lowered blood-glucose levels after the rats had eaten, but only Junuvia raised the total output of insulin by the pancreas while lowering levels of glucagon.

ROCHESTER, Minn. — Many patients with heart failure skip pills due to medication costs, according to research by the Mayo Clinic.

The study, published in the journal Mayo Clinic Proceedings, tracked the pharmacy records of 209 patients ages 60 to 86 years in Olmsted County, Minn., who were asked how often they missed doses or didn’t take their drugs at all and why.